Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 5Recruiting 1

Sponsor Class

OTHER 6INDUSTRY 6

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Endocrine 8NET 6

Conditions

Neuroendocrine Tumors 117Gastro-enteropancreatic neuroendocrine tumor 21Neoplasms 20Carcinoid Tumor 17Colorectal Neoplasms 13Carcinoma, Neuroendocrine 11Neoplasm Metastasis 10Carcinoma 10Lung Neoplasms 9Small Cell Lung Carcinoma 8Prostatic Neoplasms 8Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Sarcoma 7Pancreatic Neoplasms 7Carcinoma, Hepatocellular 7Adenoma, Islet Cell 7Stomach Neoplasms 6Serotonin Syndrome 6Pheochromocytoma 6Melanoma 6Head and Neck Neoplasms 6Digestive System Neoplasms 6Cholangiocarcinoma 6Thyroid Neoplasms 5Paraganglioma 5Ovarian Neoplasms 5Gastroenteropancreatic Neuroendocrine Tumors 5Colonic Neoplasms 5

Interventions

telotristat ethyl 1lanreotide 1Random Allocation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Serotonin Syndrome × NET × Clear all
NCT07087054 2026-04-30

CAREFNDR

Crinetics Pharmaceuticals Inc.

Phase 3 Recruiting
141 enrolled
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT03223428 2024-07-24

RELAX

TerSera Therapeutics LLC

Completed
223 enrolled 16 charts
EndocrineNET

Neuroendocrine Tumors, Serotonin Syndrome

NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed
115 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT01234168 2020-11-05

SYMNET

Ipsen

Completed
340 enrolled
EndocrineNET

Neuroendocrine Tumors, Serotonin Syndrome

NCT02299089 2017-12-15

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Camurus AB

Phase 2 Completed
12 enrolled 18 charts
EndocrineNET

Acromegaly, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡